Higher dose of Wegovy ® provided average weight loss of 21% in people with obesity - with a third achieving 25% or more - according to data presented at ADA. Results from the phase 3b STEP UP ...

SAN DIEGO, June 04, 2025--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced ...

US-based Iambic Therapeutics has concluded the dose escalation phase in its multi-centre Phase I/Ib trial of a brain-penetrant small molecule inhibitor targeting wild-type and oncogenic mutant ...

The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast cancer. Presented at: ASCO Annual Meeting; May 30-June 3, 2025; Chicago.

Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed ...

Iambic Completes Dose Escalation in Ongoing Phase 1/1B Study of Lead Program IAM1363, a Small Molecule Inhibitor of Wild-Type and Oncogenic HER2 Mutant Proteins Business Wire Jun 4, 2025 ...

Factor Zepbound for weight loss and weight management Wegovy for weight loss and weight management; Form: liquid solution in two forms, each for injection under your skin: • single-use pen ...